Skip to main content
Premium Trial:

Request an Annual Quote

Harry Hixson, Mats-Olof Wallin, George Rathmann, Ted Love, Richard Brewer, Mary Pendergast, Phillipe Chambon, Jean-Francois Formela, Martin Vogelbaum

Premium

Sequenom recruited former Amgen CEO Harry Hixson to its board, the company said Jan. 14. Hixson is currently chairman and CEO of privately held drug firm Elitra Pharmaceuticals.


Pyrosequencing named Mats-Olof Wallin CFO, capping a broad restructuring begun in October.

Wallin, 51, is currently CFO of Ortivus, a Swedish medical technology company. He will oversee Pyrosequencing’s financings in Sweden and in the US.


Hyseq and Variagenics have named six board members and a chairman to oversee the new — and still unnamed — company set to emerge Jan. 28 [see accompanying story, page 3]. From the Hyseq side, Chairman George Rathmann, 75, will retain his title at the new firm. He will be joined on the board by Hyseq compatriots Ted Love, 43; Richard Brewer, 51; and Mary Pendergast, 52. Variagenics, meantime, will chip in Phillipe Chambon, 44; Jean-Francois Formela, 46; and Martin Vogelbaum, 39.

Filed under

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.